<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958252</url>
  </required_header>
  <id_info>
    <org_study_id>1447-0004</org_study_id>
    <nct_id>NCT04958252</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1569912 Are Tolerated</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1569912 in Healthy Male Japanese Subjects (Single-blind, Partially Randomized Within Dose Groups, Placebo-controlled, Parallel-group Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, tolerability and pharmacokinetics of BI 1569912 will be assessed in healthy male&#xD;
      Japanese subjects receiving single rising doses (SRD) and multiple doses (MD) in order to&#xD;
      provide the basis for a clinical development of BI 1569912 in the indication for Major&#xD;
      Depressive Disorder (MDD) in Japan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">February 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The trial is designed single-blind. The treatments administered (active or placebo) will be blinded to subjects, but will be known to the investigators (outcome assessors). Only the current dose level will be known to the subjects due to the rising dose design.&#xD;
Subjects will be randomized within dose groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with drug-related adverse events</measure>
    <time_frame>up to 27 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SRD part: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 4 days</time_frame>
    <description>Single-rising dose (SRD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRD part: maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 4 days</time_frame>
    <description>Single-rising dose (SRD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part, after the first dose: Area under the concentration-time curve of the analyte in plasma from 0 to 24 hours (AUC0-24)</measure>
    <time_frame>up to 17 days</time_frame>
    <description>Multiple dose (MD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part, after the first dose: Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 17 days</time_frame>
    <description>Multiple dose (MD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part, after the last dose: Area under the concentration-time curve of the analyte in plasma over the dosing interval τ at steady state (AUCτ,ss)</measure>
    <time_frame>up to 17 days</time_frame>
    <description>Multiple dose (MD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD part, after the last dose: Maximum measured concentration of the analyte in plasma at steady state (Cmax,ss)</measure>
    <time_frame>up to 17 days</time_frame>
    <description>Multiple dose (MD)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose part: BI 1569912 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose part: BI 1569912 lower medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose part: BI 1569912 higher medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose part: BI 1569912 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose part: BI 1569912</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional dose group for multiple dose part may be added based on experience gained during the single dose part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1569912</intervention_name>
    <description>BI 1569912</description>
    <arm_group_label>Multiple dose part: BI 1569912</arm_group_label>
    <arm_group_label>Single dose part: BI 1569912 high dose</arm_group_label>
    <arm_group_label>Single dose part: BI 1569912 higher medium dose</arm_group_label>
    <arm_group_label>Single dose part: BI 1569912 low dose</arm_group_label>
    <arm_group_label>Single dose part: BI 1569912 lower medium dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a medical examination, vital signs (blood pressure&#xD;
             (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          -  Japanese ethnicity, according to the following criteria: born in Japan, have lived&#xD;
             outside of Japan &lt;10 years, and have parents and grandparents who are Japanese&#xD;
&#xD;
          -  Age of 20 to 45 years (inclusive)&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 25.0 kg/m2 (inclusive)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          -  Subjects who agree to minimize the risk of making their partner pregnant by fulfilling&#xD;
             any of the following criteria starting from the first administration of trial&#xD;
             medication until 90 days after last administration of trial medication&#xD;
&#xD;
               -  Use of adequate contraception, any of the following methods plus condom:&#xD;
                  intrauterine device, combined oral contraceptives that started at least 2 months&#xD;
                  prior to the first drug administration.&#xD;
&#xD;
               -  Vasectomized (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
               -  Surgical sterilization (including bilateral tubal occlusion, hysterectomy or&#xD;
                  bilateral oophorectomy) of the subject's female partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the&#xD;
             range of 40 to 99 beats per minute (bpm)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SOUSEIKAI Sumida Hospital</name>
      <address>
        <city>Tokyo, Sumida-ku</city>
        <zip>130-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoichiro Ogama</last_name>
      <phone>+81 3 56087276</phone>
      <email>yoichiro-ogama@lta-med.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

